Mortalin-MPD (mevalonate pyrophosphate decarboxylase) interactions and their role in control of cellular proliferation.
暂无分享,去创建一个
Kazunari Taira | Renu Wadhwa | S. Kaul | R. Wadhwa | Tomoko Yaguchi | K. Taira | M. Hasan | Tomoko Yaguchi | Sunil C Kaul | Md Kamrul Hasan
[1] Y. Yamori,et al. Comparison of subcellular distribution of mevalonate pyrophosphate decarboxylase between stroke-prone spontaneously hypertensive rat and Wistar Kyoto rat. , 2002, Biological & pharmaceutical bulletin.
[2] Y. Yamori,et al. Mevalonate pyrophosphate decarboxylase in stroke-prone spontaneously hypertensive rat is reduced from the age of two weeks. , 2001, Biological & pharmaceutical bulletin.
[3] M. Kitagawa,et al. Geranylgeranylpyrophosphate, a metabolite of mevalonate, regulates the cell cycle progression and DNA synthesis in human lymphocytes. , 1997, Biochemical and biophysical research communications.
[4] R. Reddel,et al. Malignant transformation of NIH3T3 cells by overexpression of mot-2 protei , 1998, Oncogene.
[5] S. Kaul,et al. Elevated levels of mortalin expression in human brain tumors. , 1997, Experimental cell research.
[6] R. Hohl. Monoterpenes as regulators of malignant cell proliferation. , 1996, Advances in experimental medicine and biology.
[7] E. Lees,et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1 , 1997, Molecular and cellular biology.
[8] O. Pereira-smith,et al. Mortalin: present and prospective , 2002, Experimental Gerontology.
[9] S. Kaul,et al. Induction of cellular senescence by transfection of cytosolic mortalin cDNA in NIH 3T3 cells. , 1993, The Journal of biological chemistry.
[10] M. McMahon,et al. Raf-1 causes growth suppression and alteration of neuroendocrine markers in DMS53 human small-cell lung cancer cells. , 1999, American journal of respiratory cell and molecular biology.
[11] F. McCormick. Ras‐related proteins in signal transduction and growth control , 1995, Molecular reproduction and development.
[12] Y. Yamori,et al. Lower mevalonate pyrophosphate decarboxylase activity is caused by the reduced amount of enzyme in stroke-prone spontaneously hypertensive rat. , 1998, Journal of biochemistry.
[13] F. Dautry,et al. Mevalonate deprivation alters the induction of fos and myc by growth factors. , 1990, Oncogene.
[14] Y. Yamori,et al. Difference in subcellular distribution between 45- and 37-kDa mevalonate pyrophosphate decarboxylase in rat liver. , 2001, Biological & pharmaceutical bulletin.
[15] M. Crouzet,et al. Stable DNA-binding yeast vector allowing high-bait expression for use in the two-hybrid system. , 1997, BioTechniques.
[16] J. R. Smith,et al. Extramitochondrial localization of mortalin/mthsp70/PBP74/GRP75. , 2000, Biochemical and biophysical research communications.
[17] S. Kaul,et al. Expression analysis of mortalin, a unique member of the Hsp70 family of proteins, in rat tissues. , 1997, Experimental cell research.
[18] S. Kaul,et al. Identification of a novel member of mouse hsp70 family. Its association with cellular mortal phenotype. , 1993, The Journal of biological chemistry.
[19] S. Mizutani,et al. Unfarnesylated transforming Ras mutant inhibits the Ras‐signaling pathway by forming a stable Ras·Raf complex in the cytosol , 1996, FEBS letters.
[20] D. Gomez,et al. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis , 1998, Breast Cancer Research and Treatment.
[21] M. Serrano. The tumor suppressor protein p16INK4a. , 1997, Experimental cell research.
[22] Y. Yamori,et al. Purification and characterization of two mevalonate pyrophosphate decarboxylases from rat liver: a novel molecular species of 37 kDa. , 1997, Journal of biochemistry.
[23] V. Ferrans,et al. Ras Proteins Induce Senescence by Altering the Intracellular Levels of Reactive Oxygen Species* , 1999, The Journal of Biological Chemistry.
[24] R. Reddel,et al. Structurally and functionally distinct mouse hsp70 family members Mot-1 and Mot-2 proteins are encoded by two alleles. , 2000, DNA research : an international journal for rapid publication of reports on genes and genomes.
[25] B. Kasiske,et al. Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? , 1996, The Lancet.
[26] S. Lowe,et al. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. , 1998, Genes & development.
[27] S. Kaul,et al. An Hsp70 family chaperone, mortalin/mthsp70/PBP74/Grp75: what, when, and where? , 2002, Cell stress & chaperones.
[28] M. McMahon,et al. Raf‐1‐induced cell cycle arrest in LNCaP human prostate cancer cells , 1999, Journal of cellular biochemistry.
[29] E. Merler,et al. Inhibition of growth factor signaling pathways by lovastatin. , 1991, Biochemical and biophysical research communications.
[30] R. Reddel,et al. Inactivation of p53 and life span extension of human diploid fibroblasts by mot‐2 , 2000 .
[31] Y. Yamori,et al. Mevalonate pyrophosphate decarboxylase is predominantly located in the cytosol of rat hepatocytes. , 2001, Biological & pharmaceutical bulletin.
[32] S. Baylin,et al. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. , 1998, The Journal of clinical investigation.
[33] R. Reddel,et al. Inactivation of Tumor Suppressor p53 by Mot-2, a hsp70 Family Member* , 1998, The Journal of Biological Chemistry.
[34] M. McMahon,et al. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1 , 1997, Oncogene.